Deep Brain Stimulation for Parkinson's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how deep brain stimulation (DBS) affects walking in people with Parkinson's disease. Researchers will study walking patterns using a special treadmill that changes speed, comparing results when the DBS device is on and off. The trial seeks participants diagnosed with Parkinson's disease who have had stable DBS for at least six months and can walk unaided. As an unphased trial, it offers participants the chance to contribute to understanding DBS's impact on mobility in Parkinson's disease.
Will I have to stop taking my current medications?
The trial requires participants to be off-medication during the study, which means you will need to stop taking your current Parkinson's medications while participating.
What prior data suggests that Deep Brain Stimulation is safe for Parkinson's Disease?
Research has shown that deep brain stimulation (DBS) is generally safe for treating Parkinson's disease. Studies indicate that DBS can improve movement, mood, and overall quality of life for people with Parkinson's. Most patients tolerate the treatment well.
Research on long-term effects found that DBS is linked to good survival rates over many years. However, like any medical procedure, risks exist. Some patients may experience complications, but these are usually rare.
Another study suggested that DBS works best during the moderate stages of Parkinson's. While there can be some risks, many people tolerate DBS well and see significant improvements in their daily lives.12345Why are researchers excited about this trial?
Researchers are excited about Deep Brain Stimulation (DBS) for Parkinson's disease because it offers a unique way to manage symptoms by directly targeting brain activity. Unlike traditional treatments like medication that focuses on balancing brain chemicals, DBS involves implanting electrodes in specific brain regions and using electrical impulses to regulate abnormal activity. This method can be adjusted and personalized for each patient, providing a level of control that standard drugs do not offer. Moreover, DBS has the potential to reduce the need for medication, minimizing their side effects and improving the quality of life for patients with Parkinson's.
What evidence suggests that Deep Brain Stimulation is effective for Parkinson's Disease?
Research has shown that Deep Brain Stimulation (DBS) can significantly benefit people with Parkinson's Disease. One study found that patients' movement abilities improved by 29% with DBS compared to medication alone. Another study discovered that DBS increased quality of life by 26%, a notable improvement over the slight decline seen in those only on medication. DBS also allows patients to reduce medication intake, which can lessen side effects. In this trial, participants will experience different DBS settings; some will have DBS turned on, while others will have it turned off, to further evaluate its effectiveness in managing symptoms and enhancing daily life for those with Parkinson's Disease.26789
Are You a Good Fit for This Trial?
This trial is for people with Parkinson's Disease who have been diagnosed by experts, have had Deep Brain Stimulation (DBS) for at least 6 months, can walk without help or aids, and do not have dementia. It's not suitable for those outside these criteria.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Participants perform baseline walking with a 1:1 speed ratio on a split-belt treadmill
Split-belt Adaptation
Participants undergo split-belt adaptation with a 2:1 speed ratio under DBS ON and DBS OFF conditions
Post-adaptation
Participants perform post-adaptation walking with a 1:1 speed ratio to assess after-effects
Follow-up
Participants are monitored for safety and effectiveness after the adaptation phases
What Are the Treatments Tested in This Trial?
Interventions
- Deep Brain Stimulation (DBS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor
NATL INST OF HLTH NIA
Collaborator
National Institute on Aging (NIA)
Collaborator